CPNP Comments on Medicare Advantage and Part D Advance Notice and Draft Call Letter: March 1, 2017

Medicare Payment Policies-Physicians Comments to CMS: August 14, 2016

Joint Pharm Org Comments to CMS on MACRA Proposed Rule: June 27, 2016

ClozapineREMS Letter to FDA: June 16, 2016

Patient Stakeholders Oppose MedPAC Recommendation to Undermine Medicares Protected Classes: June 15, 2016

CPNP Urges Inclusion of Psychiatric Pharmacists in Letter to the Editor: June 12, 2016

CPNP/ACCP Coalition Submits Comments to Hearing Focused on “Legislation to Improve and Sustain the Medicare Program": June 6, 2016

CPNP Comments on the Better Care, Lower Cost Act: March 11, 2016

CPNP Comments to Sentate Finance Chronic Care Committee: January 22, 2016

CPNP Comments on Medicare Part D Medication Therapy Management Program: October 21, 2015

CPNP Comments on International Drug Scheduling; Convention on Psychotropic Substances; Single Convention on Narcotic Drugs; Ketamine and Nine Other Substances: October 15, 2015

Letter to FDA Regarding Inclusion of Board Certified Psychiatric Pharmacists into the Clozapine REMS Enrollment Form: September 29, 2015

CPNP Comments on Reform of Requirements for Long-Term Care Facilities: September 14, 2015

Senate Committee comments on Chronc Care: June 19, 2015

May 2015-ACCP CPNP Comments Senate Finance Committee Hearing A Pathway to Improving Care for Medicare Patients with Chronic Conditions: May 14, 2015

CPNP Response-USP General Chapter 800 Hazardous Drugs – Handling in Healthcare Settings: May 4. 2015

CPNP Response-NIOSH Hazardous Drugs List for Classification of a Medication as Hazardous: June 17, 2014

Letter to Congressman Tim Murphy: April 14, 2014

PAPCC response letter to APhA: March 10, 2014

Letter to Membership on PAPCC: March 10, 2014

CMS Comment Letter-MTM Expansion-Drug Class Limitations: March 7, 2014

Better Care Act Response-Sen Wyden: March 3, 2014

CPNP Mental Health Improvement Response Letter: September 13, 2013